OBJECTIVE: To determine whether the peripheral fat wasting (lipodystrophy), which is seen in association with highly active antiretroviral therapy (HAART) that includes a nucleoside reverse transcriptase inhibitor (NRTI), is associated with a decrease in subcutaneous adipose tissue mitochondrial DNA (mtDNA) content or with large mtDNA deletions or insertions. DESIGN: A four cohort cross-sectional study. METHODS: The mtDNA content of subcutaneous fat tissue from the neck, abdomen and thigh was determined by polymerase chain reaction utilizing the amplification of three different mtDNA fragments. The results from HIV-infected patients with peripheral fat wasting following more than 6 months of NRTI-containing HAART were compared with the results from three different control cohorts: HIV-infected patients with a similar treatment history without lipodystrophy; HIV-infected patients naive to antiretroviral therapy and HIV sero-negative participants. RESULTS: A decrease in mtDNA content was found in HAART-treated HIV-infected patients with peripheral fat wasting in comparison with subjects in the control cohorts. No large mitochondrial deletions or insertions were found. CONCLUSIONS: Lipodystrophy with peripheral fat wasting following treatment with NRTI-containing HAART is associated with a decrease in subcutaneous adipose tissue mtDNA content.
OBJECTIVE: To determine whether the peripheral fat wasting (lipodystrophy), which is seen in association with highly active antiretroviral therapy (HAART) that includes a nucleoside reverse transcriptase inhibitor (NRTI), is associated with a decrease in subcutaneous adipose tissue mitochondrial DNA (mtDNA) content or with large mtDNA deletions or insertions. DESIGN: A four cohort cross-sectional study. METHODS: The mtDNA content of subcutaneous fat tissue from the neck, abdomen and thigh was determined by polymerase chain reaction utilizing the amplification of three different mtDNA fragments. The results from HIV-infectedpatients with peripheral fat wasting following more than 6 months of NRTI-containing HAART were compared with the results from three different control cohorts: HIV-infectedpatients with a similar treatment history without lipodystrophy; HIV-infectedpatients naive to antiretroviral therapy and HIV sero-negative participants. RESULTS: A decrease in mtDNA content was found in HAART-treated HIV-infectedpatients with peripheral fat wasting in comparison with subjects in the control cohorts. No large mitochondrial deletions or insertions were found. CONCLUSIONS: Lipodystrophy with peripheral fat wasting following treatment with NRTI-containing HAART is associated with a decrease in subcutaneous adipose tissue mtDNA content.
Authors: Cecilia M Shikuma; Mariana Gerschenson; Dominic Chow; Daniel E Libutti; John H Willis; James Murray; Roderick A Capaldi; Michael Marusich Journal: AIDS Res Hum Retroviruses Date: 2008-10 Impact factor: 2.205
Authors: C Hadigan; D Kamin; J Liebau; S Mazza; S Barrow; M Torriani; R Rubin; S Weise; A Fischman; S Grinspoon Journal: Am J Physiol Endocrinol Metab Date: 2005-08-30 Impact factor: 4.310
Authors: Robert C Kalayjian; John Spritzler; Roy M Matining; Susan A Fiscus; Barry H Gross; Isaac R Francis; Richard B Pollard; Michael M Lederman; Alan Landay Journal: AIDS Date: 2013-06-19 Impact factor: 4.177
Authors: Cecilia M Shikuma; Louie Mar A Gangcuangco; Deirdre A Killebrew; Daniel E Libutti; Dominic C Chow; Beau K Nakamoto; Chin Yuan Liang; Cris I P Milne; Lishomwa C Ndhlovu; Jason D Barbour; Bruce T Shiramizu; Mariana Gerschenson Journal: J Acquir Immune Defic Syndr Date: 2014-02-01 Impact factor: 3.731
Authors: Marisa Tungsiripat; Mary Ann O'Riordan; Norma Storer; Danielle Harrill; Jason Ganz; Daniel Libutti; Mariana Gerschenson; Grace A McComsey Journal: HIV Clin Trials Date: 2009 Sep-Oct
Authors: Martin Torriani; Markella V Zanni; Kathleen Fitch; Eleni Stavrou; Miriam A Bredella; Ruth Lim; Aaron M Cypess; Steven Grinspoon Journal: Antivir Ther Date: 2012-10-05